Basmisanil - Roche

Drug Profile

Basmisanil - Roche

Alternative Names: GABRA5 negative allosteric modulator (NAM) - Roche; RG-1662; RO5186582

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche
  • Class Antidementias; Oxazoles; Pyridines; Small molecules; Thiamorpholines
  • Mechanism of Action GABA A alpha 5 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Down syndrome; Neurological disorders; Schizophrenia

Most Recent Events

  • 05 Nov 2017 Hoffmann-La Roche terminates a phase II trial in Neurological disorders (In adults, In the elderly) in Spain due to low participant recruitment (NCT02928393)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Down syndrome in Japan (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Down syndrome(In volunteers) in United Kingdom (PO, Granules)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top